CTII's cell therapy for diabetes

Noteworthy

CytoTherapeutics Inc. was to announce today that it has begun Phase I trials of polymer-encapsulated islet cells that will be implanted in patients with Type I insulin-dependent diabetes and Type II diabetes, as well as in healthy volunteers...